Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

- Safety and Tumor Response Data from Dose-Escalation Study Presented at

American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC). Results demonstrated that picoplatin can be safely administered in combination with 5-fluorouracil and leucovorin (FOLPI) as a first-line option for CRC. Based on the safety data as well as the promising clinical activity observed in this trial, Poniard initiated a randomized, controlled, proof-of-concept Phase 2 trial to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed in May 2008.

"Several treatment options for metastatic CRC have been introduced in the last decade and have resulted in enhanced survival when administered as a first-line treatment. However, these treatments can cause serious side effects, including severe neuropathies that prevent patients from participating in routine daily activities and may lead to discontinuing therapy," said Robert De Jager, M.D., chief medical officer of Poniard. "We are encouraged by these preliminary results, which continue to show that picoplatin given once every four weeks as part of the FOLPI regimen is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen; both regimens have similar anti-tumor activity in first-line metastatic CRC. We are continuing to observe the study participants and look forward to presenting initial pro
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
(Date:7/10/2014)... lithium-ion batteries that power our laptops and electric vehicles ... single charge with the help of a sponge-like silicon ... replace the graphite traditionally used in one of the ... the energy storage capacity of graphite. A paper describing ... published today in Nature Communications . , "Silicon ...
(Date:7/10/2014)... theatergoers have shelled out for crude 3-D glasses, ... viewing experience. These basic devices, used to trick ... may soon be rendered obsolete with the introduction ... University researchers. , TAU doctoral students Yuval Yifat, ... efficient holography based on nanoantennas that could be ...
(Date:7/10/2014)... and NPL collaborate to bring together their track record ... academic strengths., Working with BIS and NPL the successful ... the UK. The establishment of a Graduate Institute, which ... provide a pipeline of skilled researchers. Working with the ... be grown through the creation of a series of ...
Breaking Biology Technology:New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... Annual Revenues Up, Net Loss Down, Cash Position Strong, as Pipeline ... ... (Nasdaq: EXEL ) today reported financial results for the full,year and ... $113.5 million, compared to $98.7 million in,2006. The increase in revenues for ...
... PALO ALTO, Calif., Feb. 14 Telik, Inc.,(Nasdaq: ... webcast will,be held on Thursday, February 21, 2008 at ... release earlier that day of the company,s,financial results for ... The conference call will be accessible via Telik,s ...
... Executives from Senexis,and O2H, both located in Cambridge, ... synthetic and computational chemistry services to the drug,discovery ... "We believe our collaboration with O2H leverages the ... search for new,therapeutics to treat ageing-related diseases by ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2
(Date:7/11/2014)... 11, 2014 Research and Markets ... Technology Market - Industry Analysis Size Share Growth Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... created a need for high level security in both ... authentication such as username and passwords, tokens etc. are ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... Bethesda, MD FASEB MARC (Minority Access to ... recipients for the 19th Annual International Conference on ... the 10th European Conference on Computational Biology (ECCB), ... Computational Biology (ISCB) in Vienna, Austria from July ...
... Forest Service,s Pacific Northwest Research Station presents summaries of ... carbon and forest products to lichens and invasive species. ... Alaska, 2004-2008, highlights key findings from the most recent ... Analysis (FIA) unit. Written by a group of 15 ...
... the authors, readers and editors of the Pensoft journal ... majority of respondents (84 %) are willing to publish their ... use, share or integrate with other data" said Dr Lyubomir ... incentives to publish data, the scientists mentioned that ...
Cached Biology News:New report highlights diversity and value of Alaska's coastal forests 2Data publishing policies and guidelines for biodiversity data by Pensoft 2
... is essential for hunting and analyzing ... such as EST sequencing projects, microarrays, ... kit is developed for normalization of ... intended for directional cloning. While most ...
... The Luminex 100 Instrument System ... multi-analyte assays using Upstate's Beadlyte reagents. ... the Dell computer with software version ... Sheath Delivery System. Upstate offers $2000 ...
Polyclonal Antibody to HADHB...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: